Pharmaceuticals Sends Acetavance New Drug Application for the treatment of acute pain and fever – Cadence Pharmaceuticals, : announced that it filed a New Drug Application with the U.S. Food and Drug Administration for its investigational product candidate Acetavance , for the treatment of acute pain and fever in adults and children. If approved, Acetavance new new intravenous pain medication approved in the United States in more than 20 years and the only approved intravenous agent for the treatment of fever in the United States. – Submission of the Acetavance NDA is an important milestone for Cadence and demonstrates our commitment to manufacture products that address the unmet needs in the hospital market, said Ted Schroeder, President and Chief Executive Officer of Cadence.

Post-operative use of intravenous ketorolac is due its potential to cause increased bleeding. Renal toxicity and limit the potential for increased cardiovascular events further postoperative use of NSAIDs. Dipyrone was the last injectable drug for the reduction of fever in the United States, but since it was taken off the market in 1976, there was no approved parenteral antipyretic drug.. There is a large unmet medical need for new agents to treat pain or fever in hospitalized patients can not take medications by mouth to treat.The Report broken thermometer CE , which determine the compliance with British law, and them been non accompanied by with the appropriate warnings, precautions and instructions for use.